Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Pulmonary Hypertension

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 160 articles: HTML format

Single Articles

April 2024
1. AGARWAL S, Fineman J, Cornfield DN, Alvira CM, et al
   VIEWING PULMONARY HYPERTENSION THROUGH A PEDIATRIC LENS.
   Eur Respir J. 2024 Apr 4:2301518. doi: 10.1183/13993003.01518-2023.
   PubMed    
   
   
   
2. GRYNBLAT J, Bogaard HJ, Eyries M, Meyrignac O, et al
   Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: an international multicentre study.
   Eur Respir J. 2024;63:2301634.
   PubMed     Abstract available
   
   
   
3. WOOLF B, Perry JA, Hong CC, Wilkins MR, et al
   Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension.
   Eur Respir J. 2024;63:2302031.
   PubMed     Abstract available
   
   
   March 2024
4. NAEIJE R
   High altitude travelling with pulmonary arterial hypertension.
   Eur Respir J. 2024;63:2400111.
   PubMed    
   
   
   
5. HOWARD LS, Price LC
   Systematic pulmonary embolism follow-up: why we should all do it!
   Eur Respir J. 2024;63:2400253.
   PubMed    
   
   
   February 2024
6. MULLER J, Titz A, Schneider SR, Bauer M, et al
   The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled cross-over trial.
   Eur Respir J. 2024 Feb 29:2301001. doi: 10.1183/13993003.01001-2023.
   PubMed     Abstract available
   
   
   
7. GERGES C, Montani D, Humbert M, Lang IM, et al
   Hemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.
   Eur Respir J. 2024 Feb 15:2302280. doi: 10.1183/13993003.02280-2023.
   PubMed    
   
   
   
8. DURRINGTON C, Hurdman JA, Elliot CA, Maclean R, et al
   Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry.
   Eur Respir J. 2024 Feb 1:2300846. doi: 10.1183/13993003.00846-2023.
   PubMed     Abstract available
   
   
   January 2024
9. PLUNKETT MJ, Sayegh ALC, McWilliams TJ, Sithamparanathan S, et al
   The skeletal muscle metaboreflex: a novel driver of ventilation, dyspnoea and pulmonary haemodynamics during exercise in pulmonary arterial hypertension.
   Eur Respir J. 2024;63:2300952.
   PubMed     Abstract available
   
   
   December 2023
10. TAMURA Y, Tamura Y, Shigeta A, Hosokawa K, et al
    Adult-onset idiopathic peripheral pulmonary artery stenosis.
    Eur Respir J. 2023;62:2300763.
    PubMed     Abstract available
    
    
    November 2023
11. HUMBERT M
    Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2301726.
    PubMed    
    
    
    
12. NEPTUNE ER, Cardoso WV
    Unravelling the expanding role of FGF10 signalling in lung homeostasis and maintenance.
    Eur Respir J. 2023;62:2301691.
    PubMed    
    
    
    
13. PAUSCH C, Pittrow D, Hoeper MM, Huscher D, et al
    Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.
    Eur Respir J. 2023;62:2301023.
    PubMed     Abstract available
    
    
    October 2023
14. HADZIC S, Wu CY, Gredic M, Pak O, et al
    Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice.
    Eur Respir J. 2023 Oct 26:2201606. doi: 10.1183/13993003.01606-2022.
    PubMed     Abstract available
    
    
    
15. WISSMULLER M, Wartner V, Hohmann C, Adler J, et al
    Impact of Face Masks on the Six Minute Walking Distance in Pulmonary Hypertension Patients During the COVID-19 Pandemic: A Prospective, Randomised Cross-over Study.
    Eur Respir J. 2023 Oct 12:2201454. doi: 10.1183/13993003.01454-2022.
    PubMed    
    
    
    
16. JEVNIKAR M, Solinas S, Brenot P, Lechartier B, et al
    Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension (CTEPH) with mixed anatomical lesions: a proof of concept.
    Eur Respir J. 2023 Oct 6:2300517. doi: 10.1183/13993003.00517-2023.
    PubMed    
    
    
    
17. MCNEILL JN, Roshandelpoor A, Alotaibi M, Choudhary A, et al
    The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension.
    Eur Respir J. 2023;62:2300561.
    PubMed     Abstract available
    
    
    
18. ANDRUSKA AM, Zamanian RT
    Sorting the wheat from the chaff: the innovative case of precision transpulmonary metabolomics.
    Eur Respir J. 2023;62:2301547.
    PubMed    
    
    
    September 2023
19. HAFNER F, Kindt A, Strobl K, Forster K, et al
    MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease.
    Eur Respir J. 2023 Sep 7:2202445. doi: 10.1183/13993003.02445-2022.
    PubMed     Abstract available
    
    
    
20. PRICE LC, McCabe C, Weatherald J
    Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle.
    Eur Respir J. 2023;62:2301513.
    PubMed    
    
    
    
21. SOUZA R, Badesch DB, Ghofrani HA, Gibbs JSR, et al
    Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
    Eur Respir J. 2023;62:2301107.
    PubMed     Abstract available
    
    
    August 2023
22. OLSSON KM, Fuge J, Park DH, Kamp JC, et al
    Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2301070.
    PubMed    
    
    
    
23. ALABED S, Garg P, Alandejani F, Dwivedi K, et al
    Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2202225.
    PubMed     Abstract available
    
    
    July 2023
24. PICCARI L, Blanco I, Torralba Y, Arismendi E, et al
    Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
    Eur Respir J. 2023 Jul 6:2300463. doi: 10.1183/13993003.00463-2023.
    PubMed    
    
    
    
25. YEH FC, Chen CN, Xie CY, Baxan N, et al
    TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2300204.
    PubMed     Abstract available
    
    
    
26. PAN HM, McClelland RL, Moutchia J, Appleby DH, et al
    Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2300190.
    PubMed     Abstract available
    
    
    June 2023
27. LUIJTEN D, Talerico R, Barco S, Cannegieter SC, et al
    Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis.
    Eur Respir J. 2023 Jun 15:2300449. doi: 10.1183/13993003.00449-2023.
    PubMed    
    
    
    
28. GONCHAROVA EA, Kudryashova TV, Pullamsetti SS
    Too hot? Too cold? Wnt signalling in pulmonary arterial hypertension: can we treat it "just right"?
    Eur Respir J. 2023;61:2300504.
    PubMed    
    
    
    
29. CHAKRABORTY A, Nathan A, Orcholski M, Agarwal S, et al
    Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension.
    Eur Respir J. 2023;61:2201625.
    PubMed     Abstract available
    
    
    
30. COTTIN V, Valenzuela C, Humbert M
    Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud.
    Eur Respir J. 2023;61:2300944.
    PubMed    
    
    
    
31. WAXMAN A, Restrepo-Jaramillo R, Thenappan T, Engel P, et al
    Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
    Eur Respir J. 2023;61:2202414.
    PubMed     Abstract available
    
    
    May 2023
32. DE MAN FS, Vonk Noordegraaf A
    The right ventricle tamed.
    Eur Respir J. 2023;61:2300509.
    PubMed    
    
    
    
33. SAMARANAYAKE CB, Kempny A, Naeije R, Gatzoulis M, et al
    Beta-blockade improves right ventricular diastolic function in exercising pulmonary arterial hypertension.
    Eur Respir J. 2023;61:2300144.
    PubMed     Abstract available
    
    
    April 2023
34. DE JONG CMM, Visser C, Bemelmans RHH, Boersma WG, et al
    Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism.
    Eur Respir J. 2023;61:2300171.
    PubMed    
    
    
    
35. SCHMIDT KH, Milger K, Pausch C, Huscher D, et al
    Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis.
    Eur Respir J. 2023;61:2202440.
    PubMed     Abstract available
    
    
    March 2023
36. KOUDSTAAL T, Boomars KA
    Inflammatory biomarkers in pulmonary arterial hypertension: ready for clinical implementation?
    Eur Respir J. 2023;61:2300018.
    PubMed    
    
    
    
37. BOUCLY A, Tu L, Guignabert C, Rhodes C, et al
    Cytokines as prognostic biomarkers in pulmonary arterial hypertension.
    Eur Respir J. 2023;61:2201232.
    PubMed     Abstract available
    
    
    February 2023
38. EICHSTAEDT CA, Belge C, Chung WK, Graf S, et al
    Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH.
    Eur Respir J. 2023;61:2201471.
    PubMed     Abstract available
    
    
    January 2023
39. RUBIN LJ, Naeije R
    Sotatercept for pulmonary arterial hypertension: something old and something new.
    Eur Respir J. 2023;61:2201972.
    PubMed    
    
    
    
40. PRICE LC, Weatherald J
    The new 2022 pulmonary hypertension guidelines: some small steps and some giant leaps forward for evidence-based care.
    Eur Respir J. 2023;61:2202150.
    PubMed    
    
    
    
41. HUMBERT M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, et al
    Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
    Eur Respir J. 2023;61:2201347.
    PubMed     Abstract available
    
    
    December 2022
42. GALKIN A, Sitapara R, Clemons B, Garcia E, et al
    Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
    Eur Respir J. 2022;60:2102356.
    PubMed     Abstract available
    
    
    
43. ORMISTON ML, Jankov RP, Stewart DJ
    Oh NO! Loss of PHD2 leads to "radical" changes in the lung vasculature.
    Eur Respir J. 2022;60:2201776.
    PubMed    
    
    
    November 2022
44. SHU T, Zhang J, Zhou Y, Chen Z, et al
    Eosinophils Protect Against Pulmonary Hypertension through 14-HDHA and 17-HDHA.
    Eur Respir J. 2022 Nov 24:2200582. doi: 10.1183/13993003.00582-2022.
    PubMed     Abstract available
    
    
    October 2022
45. MICKAEL C, Lee MH, Graham BB
    The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
46. BADAGLIACCA R, Papa S, D'Alto M, Ghio S, et al
    The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
47. ADNOT S, Lipskaia L, Bischof O
    What is hidden behind a pulmonary hypertensive, fibrotic and inflammatory phenotype?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    September 2022
48. RIOU M, Canuet M, Ghigna MR, Eyries M, et al
    First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.
    Eur Respir J. 2022 Sep 30. pii: 13993003.01197-2022.
    PubMed    
    
    
    
49. HASSAN HJ, Naranjo M, Kazzi B, Housten-Harris T, et al
    Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index versus stroke volume index.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
50. DOUSCHAN P, Tello K, Rieth AJ, Wiedenroth CB, et al
    Right ventricular-pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    August 2022
51. HUMBERT M, Kovacs G, Hoeper MM, Badagliacca R, et al
    2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
    Eur Respir J. 2022 Aug 25. pii: 13993003.00879-2022.
    PubMed    
    
    
    
52. VAN DE VEERDONK MC, Vonk-Noordegraaf A, Vachiery JL
    Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
53. LECHARTIER B, Girerd B, Eyries M, Beurnier A, et al
    Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
54. RAI N, Sydykov A, Kojonazarov B, Wilhelm J, et al
    Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    July 2022
55. MADOUN S, Piliero N, Guillien A, Salvat M, et al
    Improved ventilatory efficiency to evidence haemodynamic improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2022 Jul 27. pii: 13993003.00762-2022.
    PubMed    
    
    
    
56. LIU B, Peng Y, Yi D, Machireddy N, et al
    Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension.
    Eur Respir J. 2022 Jul 7. pii: 13993003.02643-2021.
    PubMed     Abstract available
    
    
    
57. STUBBS H, Lua S, Brewis M, Johnson M, et al
    COMPERA 2.0 risk stratification in medically-managed chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2022 Jul 7. pii: 13993003.00313-2022.
    PubMed    
    
    
    
58. GHOFRANI HA
    Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
59. DU M, Jiang H, Liu H, Zhao X, et al
    Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function via ID genes.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
60. HOEPER MM, Pausch C, Olsson KM, Huscher D, et al
    COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
61. SWINNEN K, Bijnens E, Casas L, Nawrot TS, et al
    Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    June 2022
62. CERTAIN MC, Baron A, Turpin M, Ebstein N, et al
    Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units.
    Eur Respir J. 2022 Jun 9. pii: 13993003.00107-2022.
    PubMed    
    
    
    
63. ALI MK, Schimmel K, Zhao L, Chen CK, et al
    The role of circular RNAs in pulmonary hypertension.
    Eur Respir J. 2022 Jun 9. pii: 13993003.00012-2022.
    PubMed     Abstract available
    
    
    
64. BOUCLY A, Humbert M, Sitbon O
    To be or not to be... treated with initial combination therapy, that is the (PAH) question.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
65. HOEPER MM, Pausch C, Grunig E, Staehler G, et al
    Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
66. ZELT JGE, Sugarman J, Weatherald J, Partridge ACR, et al
    Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
67. VAN DER HAVE O, Westoo C, Ahrne F, Tian X, et al
    Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
68. NAEIJE R, Richter MJ, Rubin LJ
    The physiological basis of pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
69. WESSELS JN, Mouratoglou SA, van Wezenbeek J, Handoko ML, et al
    Right atrial function is associated with right venticular diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
70. JUTANT EM, Tu L, Thuillet R, Picard V, et al
    Erythrocytes are altered in pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    May 2022
71. NEDER JA, Phillips DB, O'Donnell DE, Dempsey JA, et al
    Excess ventilation and exertional dyspnoea in heart failure and pulmonary hypertension.
    Eur Respir J. 2022 May 26. pii: 13993003.00144-2022.
    PubMed     Abstract available
    
    
    
72. AZZO L, Ali YS, Vaqar S, Dauriat G, et al
    Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort.
    Eur Respir J. 2022 May 20. pii: 13993003.02897-2021.
    PubMed     Abstract available
    
    
    
73. BENATTIA A, Bugnet E, Walter-Petrich A, de Margerie-Mellon C, et al
    Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    March 2022
74. TOSHNER M, Church C, Harbaum L, Rhodes C, et al
    Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    February 2022
75. OLSSON KM, Richter MJ, Kamp JC, Gall H, et al
    Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation.
    Eur Respir J. 2022 Feb 10. pii: 13993003.03087-2021.
    PubMed    
    
    
    January 2022
76. D'ALTO M, Di Maio M, Romeo E, Argiento P, et al
    Echocardiographic probability of pulmonary hypertension: a validation study.
    Eur Respir J. 2022 Jan 7. pii: 13993003.02548-2021.
    PubMed     Abstract available
    
    
    December 2021
77. LAMMI MR, Samant S, Tran HV, Uddo RB, et al
    Jugular venous ultrasound predicts outcomes in pulmonary hypertension outpatients.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02591-2021.
    PubMed    
    
    
    
78. 
    "Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats." R. Dumitrascu, C. Kulcke, M. Konigshoff, et al. Eur Respir J 2011; 37: 1104-1118.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
79. KHOURI C, Hlavaty A, Roustit M, Cracowski JL, et al
    Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
80. BRAAMS NJ, Boon GJAM, de Man FS, van Es J, et al
    Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    November 2021
81. OGO T, Shimokawahara H, Kinoshita H, Sakao S, et al
    Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2021 Nov 25. pii: 13993003.01694-2021.
    PubMed     Abstract available
    
    
    
82. BOUCLY A, Weatherald J, Savale L, de Groote P, et al
    External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry.
    Eur Respir J. 2021 Nov 4. pii: 13993003.02419-2021.
    PubMed     Abstract available
    
    
    
83. GAZENGEL P, Hascoet S, Amsallem M, Savale L, et al
    Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension.
    Eur Respir J. 2021 Nov 4. pii: 13993003.02388-2021.
    PubMed    
    
    
    
84. KOTSIMBOS T, Kaye D, Keating D
    Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
85. LE RIBEUZ H, To L, Ghigna MR, Martin C, et al
    Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    October 2021
86. CALLEJO M, Blanco I, Barbera JA, Perez-Vizcaino F, et al
    Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
87. VALENTIN S, Maurac A, Sitbon O, Beurnier A, et al
    Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    
88. PETERS EL, Bogaard HJ, Vonk Noordegraaf A, de Man FS, et al
    Neurohormonal modulation in pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    September 2021
89. GREDIC M, Wu CY, Hadzic S, Pak O, et al
    Myeloid cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice.
    Eur Respir J. 2021 Sep 2. pii: 13993003.01153-2021.
    PubMed     Abstract available
    
    
    
90. SAVALE L, Vuillard C, Pichon J, Boucly A, et al
    Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
91. WU Y, Wharton J, Walters R, Vasilaki E, et al
    The pathophysiological role of novel pulmonary arterial hypertension gene SOX17.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    
92. EVANS CE, Cober ND, Dai Z, Stewart DJ, et al
    Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    August 2021
93. OLSSON KM, Hoeper MM, Pausch C, Grunig E, et al
    Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.
    Eur Respir J. 2021 Aug 12. pii: 13993003.01483-2021.
    PubMed    
    
    
    
94. KIELY DG, Condliffe R
    Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
95. DECLERCQ M, Treps L, Bousfia S, Carmeliet P, et al
    Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
96. SAVALE L, Akagi S, Tu L, Cumont A, et al
    Serum and pulmonary uric acid in pulmonary arterial hypertension.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    July 2021
97. MORRELL NW
    Screening asymptomatic BMPR2 mutation carriers: a new frontier for pulmonary hypertension physicians?
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
98. MONTANI D, Girerd B, Jais X, Laveneziana P, et al
    Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    June 2021
99. ABMAN SH, Mullen MP, Sleeper LA, Austin ED, et al
    Characterisation of Pediatric Pulmonary Hypertensive Vascular Disease from the PPHNet Registry.
    Eur Respir J. 2021 Jun 17. pii: 13993003.03337-2020.
    PubMed     Abstract available
    
    
    
100. LAUNAY D, Sanges S, Sobanski V
     Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension.
     Eur Respir J. 2021;57.
     PubMed    
     
     
     
101. PEREZ-OLIVARES C, Segura de la Cal T, Flox-Camacho A, Nuche J, et al
     The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease.
     Eur Respir J. 2021;57.
     PubMed    
     
     
     
102. BAUER Y, de Bernard S, Hickey P, Ballard K, et al
     Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     May 2021
103. STEWART S, Chan YK, Playford D, Strange GA, et al
     Mild pulmonary hypertension and premature mortality among 154 956 men and women undergoing routine echocardiography.
     Eur Respir J. 2021 May 28. pii: 13993003.00832-2021.
     PubMed     Abstract available
     
     
     
104. AWADA C, Grobs Y, Wu WH, Habbout K, et al
     R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models.
     Eur Respir J. 2021;57.
     PubMed    
     
     
     
105. RAHAGHI FN, Hilton JF, Correa RA, Loureiro C, et al
     Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension.
     Eur Respir J. 2021;57.
     PubMed    
     
     
     April 2021
106. OLDHAM WM, Hess E, Waldo SW, Humbert M, et al
     Integrating hemodynamics identifies an extreme pulmonary hypertension phenotype.
     Eur Respir J. 2021 Apr 8. pii: 13993003.04625-2020.
     PubMed    
     
     
     
107. LLUCIA-VALLDEPERAS A, van Wezenbeek J, Goumans MJ, de Man FS, et al
     The battle of new biomarkers for right heart failure in pulmonary hypertension: is the queen of hearts NT-proBNP defeated at last?
     Eur Respir J. 2021;57.
     PubMed    
     
     
     
108. AMSALLEM M, Sweatt AJ, Arthur Ataam J, Guihaire J, et al
     Targeted proteomics of right heart adaptation to pulmonary arterial hypertension.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     March 2021
109. MACIAS D, Moore S, Crosby A, Southwood M, et al
     Targeting HIF2alpha-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     February 2021
110. ULRICH S, Grunig E
     The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment.
     Eur Respir J. 2021;57.
     PubMed    
     
     
     
111. BORGESE M, Badesch D, Bull T, Chakinala M, et al
     EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     
112. LEWIS RA, Armstrong I, Bergbaum C, Brewis MJ, et al
     EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     January 2021
113. SWINNEN K, Bijnens E, Casas L, Nawrot TS, et al
     Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy.
     Eur Respir J. 2021 Jan 21. pii: 13993003.02680-2020.
     PubMed    
     
     
     
114. REMY-JARDIN M, Ryerson CJ, Schiebler ML, Leung ANC, et al
     Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     
115. BOGAARD HJ, Sitbon O
     Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated.
     Eur Respir J. 2021;57.
     PubMed    
     
     
     
116. HAARMAN MG, Levy M, Roofthooft MTR, Douwes JM, et al
     Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension.
     Eur Respir J. 2021;57.
     PubMed     Abstract available
     
     
     December 2020
117. DELCROIX M, Torbicki A, Gopalan D, Sitbon O, et al
     ERS Statement on Chronic Thromboembolic Pulmonary Hypertension.
     Eur Respir J. 2020 Dec 17. pii: 13993003.02828-2020.
     PubMed     Abstract available
     
     
     November 2020
118. KERANOV S, Dorr O, Jafari L, Troidl C, et al
     CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension.
     Eur Respir J. 2020 Nov 12. pii: 13993003.01192-2019.
     PubMed     Abstract available
     
     
     
119. CONDLIFFE R, Kiely DG, Lewis RA
     Mild parenchymal lung disease is still lung disease.
     Eur Respir J. 2020;56.
     PubMed    
     
     
     
120. GODINAS L, Harari S, Barbera JA, Montani D, et al
     Mild parenchymal lung disease is still lung disease.
     Eur Respir J. 2020;56.
     PubMed    
     
     
     
121. RHODES CJ
     The cancer hypothesis of pulmonary arterial hypertension: are polyamines the new Warburg?
     Eur Respir J. 2020;56.
     PubMed    
     
     
     October 2020
122. CAMBOULIVE A, Jutant EM, Savale L, Jais X, et al
     Reversible pulmonary hypertension associated with multivisceral Whipple's disease.
     Eur Respir J. 2020 Oct 22. pii: 13993003.03132-2020.
     PubMed    
     
     
     
123. SWIETLIK EM, Ghataorhe P, Zalewska KI, Wharton J, et al
     Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension.
     Eur Respir J. 2020 Oct 15. pii: 13993003.03201-2020.
     PubMed     Abstract available
     
     
     September 2020
124. BADAGLIACCA R, Vizza CD
     Imaging risk in pulmonary arterial hypertension.
     Eur Respir J. 2020;56.
     PubMed    
     
     
     August 2020
125. GUIGNABERT C, Humbert M
     Targeting Transforming Growth Factor Beta Receptors in Pulmonary Hypertension.
     Eur Respir J. 2020 Aug 13. pii: 13993003.02341-2020.
     PubMed     Abstract available
     
     
     
126. ADIR Y, Humbert M, Chaouat A
     Sleep-related breathing disorders and pulmonary hypertension.
     Eur Respir J. 2020 Aug 3. pii: 13993003.02258-2020.
     PubMed     Abstract available
     
     
     
127. SOFIANOPOULOU E, Church C, Coghlan G, Howard L, et al
     Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
     Eur Respir J. 2020;56.
     PubMed    
     
     
     July 2020
128. JEVNIKAR M, Montani D, Savale L, Seferian A, et al
     Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems.
     Eur Respir J. 2020 Jul 16. pii: 13993003.02208-2020.
     PubMed    
     
     
     
129. MARON BA, Humbert M
     Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.
     Eur Respir J. 2020;56.
     PubMed    
     
     
     June 2020
130. NEWNHAM M, Bunclark K, Abraham N, Ali S, et al
     CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension (CTEPH).
     Eur Respir J. 2020 Jun 8. pii: 13993003.02096-2019.
     PubMed     Abstract available
     
     
     
131. BEHR J, Hoeper MM
     Subtle signs - red flags.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     May 2020
132. OLSSON KM, Fuge J, Brod T, Kamp JC, et al
     Oral iron supplementation with ferric maltol in patients with pulmonary hypertension.
     Eur Respir J. 2020 May 22. pii: 13993003.00616-2020.
     PubMed    
     
     
     
133. DODSON MW, Sumner K, Carlsen J, Cirulis MM, et al
     The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension.
     Eur Respir J. 2020 May 22. pii: 13993003.00774-2020.
     PubMed    
     
     
     
134. LICHTBLAU M, Saxer S, Furian M, Mayer L, et al
     Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m.
     Eur Respir J. 2020 May 19. pii: 13993003.02474-2019.
     PubMed     Abstract available
     
     
     
135. SITBON O, Reis A, Humbert M, Vonk Noordegraaf A, et al
     Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     
136. VIS D, Boucly A, Humbert M, Weatherald J, et al
     Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
     Eur Respir J. 2020;55.
     PubMed    
     
     
     
137. AUSTIN ED, Elliott CG
     TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     
138. JANSEN SMA, van den Heuvel L, Meijboom LJ, Alsters SIM, et al
     Correspondence regarding "T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease": a single-centre case series.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     
139. THORE P, Girerd B, Jais X, Savale L, et al
     Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation.
     Eur Respir J. 2020;55.
     PubMed     Abstract available
     
     
     
140. GHIO S, Crimi G, Guida S, Valentini A, et al
     Magnetic resonance imaging of pulmonary arterial compliance after pulmonary endarterectomy.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     April 2020
141. YOGESWARAN A, Richter MJ, Sommer N, Ghofrani HA, et al
     Evaluation of pulmonary hypertension by right heart catheterisation - does timing matter?
     Eur Respir J. 2020 Apr 29. pii: 13993003.01892-2019.
     PubMed    
     
     
     
142. KIKUCHI H, Goda A, Takeuchi K, Inami T, et al
     Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty.
     Eur Respir J. 2020 Apr 20. pii: 13993003.01982-2019.
     PubMed     Abstract available
     
     
     
143. DUAN D, Gu C, Jun JC
     Altered metabolism in pulmonary hypertension: fuelling the fire or just smoke?
     Eur Respir J. 2020;55.
     PubMed    
     
     
     
144. TOSHNER M, Rothman A
     IL-6 in pulmonary hypertension: why novel is not always best.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     
145. BOTROS L, Vonk Noordegraaf A, Aman J
     Vanishing vessels aboding pulmonary disease: a role for VEGFR2.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     March 2020
146. KLOK FA, Couturaud F, Delcroix M, Humbert M, et al
     Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.
     Eur Respir J. 2020 Mar 17. pii: 13993003.00189-2020.
     PubMed     Abstract available
     
     
     
147. SHLOBIN OA, Kouranos V, Barnett SD, Alhamad EH, et al
     Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry.
     Eur Respir J. 2020 Mar 5. pii: 13993003.01747-2019.
     PubMed     Abstract available
     
     
     
148. FRUMP AL, Lahm T
     Tips for success in pulmonary hypertension treatment: progress in isolating endothelial cells from pulmonary artery catheters.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     February 2020
149. PABST S, Grohe C, Skowasch D
     Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies.
     Eur Respir J. 2020;55.
     PubMed    
     
     
     January 2020
150. 
     "Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease." Laurent Savale, Anoosha Habibi, Francois Lionnet, Bernard Maitre, Vincent Cottin, Xavier Jais, Ari Chaouat, Elise Artaud-Macari, Matthieu Canuet, Gregoir
     Eur Respir J. 2020;55.
     PubMed    
     
     
     December 2019
151. BOUVARD C, Genet N, Phan C, Rode B, et al
     Connexin 43 Is a Promising Target for Pulmonary Hypertension due To Hypoxemic Lung Disease.
     Eur Respir J. 2019 Dec 20. pii: 13993003.00169-2019.
     PubMed     Abstract available
     
     
     
152. WAYPA GB, Schumacker PT
     Roles of HIF1 and HIF2 in pulmonary hypertension: it all depends on the context.
     Eur Respir J. 2019;54.
     PubMed    
     
     
     November 2019
153. BOUCLY A, Morelot-Panzini C, Garcia G, Weatherald J, et al
     Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension.
     Eur Respir J. 2019 Nov 26. pii: 13993003.02108-2018.
     PubMed     Abstract available
     
     
     
154. GRUNIG E, Benjamin N, Eichstaedt CA, Peacock AJ, et al
     Multicentre trials on specialised exercise training and rehabilitation are useful in patients with pulmonary hypertension.
     Eur Respir J. 2019;54.
     PubMed    
     
     
     October 2019
155. LEVY M, Moshous D, Szezepanski I, Galmiche L, et al
     Pulmonary hypertension after bone marrow transplantation in children.
     Eur Respir J. 2019 Oct 24. pii: 13993003.00612-2019.
     PubMed     Abstract available
     
     
     
156. 
     "Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?" Irene M. Lang and Hiromi Matsubara. Eur Respir J 2019; 53: 1900843.
     Eur Respir J. 2019;54.
     PubMed    
     
     
     
157. LANG IM, Matsubara H
     Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?
     Eur Respir J. 2019;54.
     PubMed    
     
     
     
158. JAIS X, Brenot P, Montani D, Fadel E, et al
     A roadmap for management of chronic thromboembolic pulmonary hypertension.
     Eur Respir J. 2019;54.
     PubMed    
     
     
     March 2019
159. ROSENZWEIG EB, Abman SH, Berger RMF
     Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns.
     Eur Respir J. 2019;53.
     PubMed    
     
     
     
160. CALCATERRA G, Fanos V, Bassareo PP
     Still puzzling about a clear definition of pulmonary arterial hypertension in newborns.
     Eur Respir J. 2019;53.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Pulmonary Hypertension is free of charge.